DrugPatentWatch Database Preview
Astellas Company Profile
» See Plans and Pricing
What is the competitive landscape for ASTELLAS, and when can generic versions of ASTELLAS drugs launch?
ASTELLAS has thirty-five approved drugs.
There are twelve US patents protecting ASTELLAS drugs. There is one tentative approval on ASTELLAS drugs.
There are two hundred and eighty-one patent family members on ASTELLAS drugs in thirty-nine countries and sixty supplementary protection certificates in eighteen countries.
Summary for Astellas
International Patents: | 281 |
US Patents: | 12 |
Tradenames: | 19 |
Ingredients: | 14 |
NDAs: | 35 |
Patent Litigation for Astellas: | See patent lawsuits for Astellas |
Drugs and US Patents for Astellas
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Astellas | ARISTOCORT | triamcinolone acetonide | CREAM;TOPICAL | 083017-003 | Approved Prior to Jan 1, 1982 | DISCN | No | No | Start Trial | Start Trial | |||||
Astellas | VESICARE LS | solifenacin succinate | SUSPENSION;ORAL | 209529-001 | May 26, 2020 | RX | Yes | Yes | Start Trial | Start Trial | |||||
Astellas | AMBISOME | amphotericin b | INJECTABLE, LIPOSOMAL;INJECTION | 050740-001 | Aug 11, 1997 | RX | Yes | Yes | Start Trial | Start Trial | |||||
Astellas | VESICARE LS | solifenacin succinate | SUSPENSION;ORAL | 209529-001 | May 26, 2020 | RX | Yes | Yes | Start Trial | Start Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Astellas
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Astellas | LEXISCAN | regadenoson | SOLUTION;INTRAVENOUS | 022161-001 | Apr 10, 2008 | 7,655,637 | Start Trial |
Astellas | LEXISCAN | regadenoson | SOLUTION;INTRAVENOUS | 022161-001 | Apr 10, 2008 | 8,470,801 | Start Trial |
Astellas | MYCAMINE | micafungin sodium | INJECTABLE;INTRAVENOUS | 021506-002 | Mar 16, 2005 | 6,107,458 | Start Trial |
Astellas | LEXISCAN | regadenoson | SOLUTION;INTRAVENOUS | 022161-001 | Apr 10, 2008 | 8,133,879 | Start Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for ASTELLAS drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Capsules | 40 mg | ➤ Subscribe | 2016-08-31 |
➤ Subscribe | Injection | 3 mg/mL, 20 mL and 30 mL vials | ➤ Subscribe | 2005-04-18 |
➤ Subscribe | Injection | 0.08 mg/mL, 5 mL vial | ➤ Subscribe | 2012-04-10 |
➤ Subscribe | Extended-release Capsules | 0.5 mg, 1 mg, and 5 mg | ➤ Subscribe | 2013-11-15 |
➤ Subscribe | For Injection | 50 mg/vial and 100 mg/vial | ➤ Subscribe | 2014-06-16 |
➤ Subscribe | Injection | 3 mg/mL, 20 mL and 30 mL vials | ➤ Subscribe | 2005-04-16 |
➤ Subscribe | Tablets | 5 mg and 10 mg | ➤ Subscribe | 2009-04-08 |
International Patents for Astellas Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
China | 1167709 | Start Trial |
Serbia | 57045 | Start Trial |
Denmark | 1280795 | Start Trial |
South Korea | 101431407 | Start Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Astellas Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1893196 | PA2013029,C1893196 | Lithuania | Start Trial | PRODUCT NAME: ENZALUTAMIDUM; REGISTRATION NO/DATE: EU/1/13/846 20130625 |
1280795 | 2015/073 | Ireland | Start Trial | PRODUCT NAME: ISAVUCONAZOLE AS ISAVUCONAZONIUM SULFATE OR AS ISAVUCONAZONIUM SALT WITH ANY OTHER PHARMACEUTICALLY ACCEPTABLE ANION, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, HYDRATE, OR SOLVATE; REGISTRATION NO/DATE: EU/1/15/1036 20151015 |
0801067 | C00801067/01 | Switzerland | Start Trial | PRODUCT NAME: SOLIFENACIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 57203 12.05.2006 |
1189916 | 392 | Finland | Start Trial | |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.